Plasma Peptides and Mortality in Dialysis Patients
Author Information
Author(s): Gouya Ghazaleh, Gisela Sturm, Claudia Lamina, Emanuel Zitt, Otto Freistätter, Joachim Struck, Michael Wolzt, Florian Knoll, Friederike Lins, Karl Lhotta, Ulrich Neyer, Florian Kronenberg
Primary Institution: Medical University Vienna
Hypothesis
The study investigates the association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide levels with mortality in dialysis patients.
Conclusion
High levels of MR-proANP and MR-proADM are associated with increased all-cause and cardiovascular mortality in incident dialysis patients.
Supporting Evidence
- 43% of the patients died during the follow-up period, with cardiovascular events accounting for 43% of these deaths.
- Both MR-proANP and MR-proADM levels were significantly higher in non-survivors compared to survivors.
- Patients with both peptides in the upper tertile had a threefold higher risk of all-cause mortality.
Takeaway
This study found that two specific proteins in the blood can help predict if dialysis patients are at risk of dying, especially if their levels are very high.
Methodology
A prospective cohort study of 201 incident dialysis patients was conducted, measuring plasma levels of MR-proANP and MR-proADM and following patients for mortality outcomes.
Potential Biases
Potential bias due to the exclusion of patients with malignant tumors and reliance on a single center for patient recruitment.
Limitations
The study had a relatively small sample size and included only Caucasian patients from a specific region, limiting generalizability.
Participant Demographics
The cohort consisted of 201 incident dialysis patients, predominantly Caucasian, with a mean age of 61 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI for HRs provided in the results
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website